The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Abstract
The link between plasminogen activator inhibitor (PAI)-1 and the metabolic syndrome with obesity was established many years ago. Increased PAI-1 level can be now considered a true component of the syndrome. The metabolic syndrome is associated with an increased risk of developing cardiovascular disease, and PAI-1 overexpression may participate in this process. The mechanisms of PAI-1 overexpression during obesity are complex, and it is conceivable that several inducers are involved at the same time at several sites of synthesis. Interestingly, recent in vitro and in vivo studies showed that besides its role in atherothrombosis, PAI-1 is also implicated in adipose tissue development and in the control of insulin signaling in adipocytes. These findings suggest PAI-1 inhibitors serve in the control of atherothrombosis and insulin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It may be particularly relevant that risk factors for developing severe COVID-19 such as advanced age, obesity, diabetes, and vascular disease are all associated with increased plasma PAI-1 concentrations (59, 60).”
From Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19 (2021) · cites this paper as [59]
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Eckel, R. H., Grundy, S. M., & Zimmet, P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,755
Increased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508
Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice
Turek, F. W., Joshu, C., Kohsaka, A., Lin, E., Ivanova, G., McDearmon, E., Laposky, A., Losee-Olson, S., Easton, A., Jensen, D. R., et al. (2005) · Science · doi:10.1126/science.1108750 · Cited by 2,485
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Malik, S., Wong, N. D., Franklin, S. S., Kamath, T. V., L'Italien, G. J., Pio, J. R., & Williams, G. R. (2004) · Circulation · doi:10.1161/01.cir.0000140677.20606.0e · Cited by 1,837
Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Research works printed but not linked: 22
- 10.1161/circ.99.19.2496 · DOI
- 10.1161/circ.94.9.2057 · DOI
- 10.1161/circ.98.21.2241 · DOI
- 10.1161/circ.91.5.1432 · DOI
- 10.1161/atvb.18.1.84 · DOI
- 10.1161/atv91.13.2.8427853 · DOI
- 10.1161/circ.97.22.2213 · DOI
- 10.1161/atvb.21.8.1378 · DOI
- 10.1161/circ.93.1.106 · DOI
- 10.1161/atvb.22.1.173 · DOI
- 10.1161/atvb.16.3.368 · DOI
- 2005, Biochem Biophys Res Commun, 19, 30
- 1999, J Clin Endocrinol Metab, 84, 4097
- 10.1161/atvb.18.11.1679 · DOI
- 10.1161/res.85.2.208 · DOI
- 1990, Fibrinolysis, 4, 93
- 10.1161/hyp.32.6.965 · DOI
- 10.1161/hyp.37.5.1336 · DOI
- 2004, PLoS Biol, 2, 1893
- 10.1161/atv91.11.1.1670989 · DOI
- Crandall DJ Quinet EM El Ayachi S Hreha AL Leik CE SavioDA Juhan-Vague I Alessi MC. Modulation of adipose tissue evelopment by pharmacologic inhibition of PAI-1. Arterioscler Thromb Vasc Biol . In press
- 10.1161/atvb.20.4.1150 · DOI
Cited by
Sorted by citations
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
RetractedAdipokines: The missing link between insulin resistance and obesity
Antuna-Puente, B., Fève, B., Fellahi, S., & Bastard, J. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.09.004 · Cited by 760
Pathophysiology of the metabolic syndrome
McCracken, E., Monaghan, M., & Sreenivasan, S. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.09.004 · Cited by 785
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 470
Metadata
- Authors
- Alessi, M.-C., & Juhan-Vague, I.
- Affiliations
- Inserm (FR)
- From the Laboratory of Hematology, INSERM UMR 626, Faculty of Medicine, Marseilles, France.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2006-10
- Volume
- 26
- Issue
- 10
- Pages
- 2200-2207
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2120559894
- Cited by
- 390
- References
- 124
- Citations by year
- 2026: 17 · 2025: 16 · 2024: 22 · 2023: 14 · 2022: 24 · 2021: 19 · 2020: 11 · 2019: 13 · 2018: 12 · 2017: 18 · 2016: 23 · 2015: 17 · 2014: 16 · 2013: 22 · 2012: 19
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Arteriosclerosis Thrombosis and Vascular Biology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- plasminogen activator inhibitor-1, metabolic syndrome, obesity, cardiovascular risk, atherothrombosis, insulin resistance, adipose tissue development, PAI-1 inhibitors
- MeSH terms
- Cardiovascular Diseases, Humans, Obesity, Plasminogen Activator Inhibitor 1, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
